Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (GH) announced upcoming presentations at the American College of Gastroenterology (ACG) 2024 Annual Meeting highlighting the importance of blood-based colorectal cancer (CRC) screening. A key study of over 350,000 patients revealed that less than 50% of patients completed recommended repeat stool-based CRC screening over a four-year period. The company will also present data from the ECLIPSE study examining one-year outcomes of individuals tested with their Shield™ blood test, showing no difference in non-colorectal malignancy rates between positive and negative test results.
Guardant Health (Nasdaq: GH) announced the appointment of Roberto A. Mignone to its board of directors. Mignone, the Founder and Managing Partner of Bridger Management , brings healthcare industry expertise and business strategy experience to the company. He currently serves as co-Vice Chairman at NYU Langone Medical Center and board member at Teva Pharmaceuticals. The appointment follows Guardant Health's FDA approval of Shield, its early-stage colorectal cancer screening product.
Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced it will report its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company management will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Interested parties can access the live audio webcast on the 'Investors' section of the Guardant Health website at www.guardanthealth.com. For those unable to attend the live event, an archived version of the webcast will be available for replay after the call.
The GOZILA study, published in Nature Medicine, demonstrates that using Guardant360 CDx liquid biopsy for targeted cancer treatment can significantly extend patient survival. The study, involving 4,037 patients with advanced gastrointestinal tumors, found that 24% of participants received targeted treatment based on the test results. Patients who received personalized treatment guided by liquid biopsy results lived approximately twice as long as those who did not, with a median survival of 18.6 months compared to 9.9 months. This research, led by the National Cancer Center Hospital East in Japan, suggests a potential paradigm shift in cancer treatment by demonstrating the survival-extending effect of liquid biopsy-based personalized cancer treatment across various cancer types.
Guardant Health (Nasdaq: GH) announced its participation in the European Society for Medical Oncology Congress (ESMO) 2024 in Barcelona. The company will present data demonstrating the performance of its precision oncology technology across multiple advanced tumor types. Key highlights include:
1. Guardant Reveal™ minimal residual disease test data in locally advanced rectal cancer patients (NO-CUT trial).
2. Guardant360® findings for therapy selection in advanced breast cancer and other solid tumors.
3. Guardant Infinity™ platform results for response monitoring in advanced non-small cell lung cancer (NSCLC).
The presentations aim to showcase the value of Guardant's liquid biopsy technology in informing therapy selection and treatment management across various cancer stages.
Guardant Health (Nasdaq: GH) has announced a partnership with Policlinico Gemelli, a leading Italian hospital, to establish an in-house liquid biopsy testing service in Italy. This collaboration will enable on-site analysis of Guardant360® CDx liquid biopsy tests at Policlinico Gemelli's facilities in Rome. The partnership aims to serve both clinical research and patient care needs, marking one of the first dedicated liquid biopsy testing facilities within an Italian hospital system.
Policlinico Gemelli, serving thousands of cancer patients annually, will now offer advanced diagnostics for precision oncology. This initiative aligns with Guardant Health's mission to expand access to innovative cancer diagnostics globally. In 2024, Guardant Health received IVDR certification for its Guardant360® CDx blood test, allowing for tumor mutation profiling and companion diagnostic indications in various solid cancers.
Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. The company's management will take part in a fireside chat on Thursday, September 5th at 11:30 a.m. ET.
Interested parties can access live and archived webcasts of the sessions on the 'Investors' section of the company's website at www.guardanthealth.com. This event provides an opportunity for Guardant Health to showcase its advancements in precision oncology and engage with industry professionals and investors.
Guardant Health (Nasdaq: GH) is set to ring the Nasdaq opening bell on August 28, 2024, celebrating the launch of their Shield™ blood test for colorectal cancer screening. This FDA-approved test offers a more comfortable alternative for early cancer detection, potentially improving survival rates.
The event marks nearly six years since Guardant's IPO bell-ringing. Co-CEO AmirAli Talasaz emphasized the significance of this milestone for the company, liquid biopsy field, and patients. The ceremony will be broadcast live at 8:30 a.m. Eastern Time, followed by a Behind the Bell interview with management.
Guardant's team will be available in New York City on August 28-29 for media interviews and investor meetings, highlighting the company's commitment to advancing precision oncology.
Guardant Health, a leader in precision oncology, announced participation in key investor conferences. The company will be present at the Canaccord Genuity 44th Annual Growth Conference in Boston, MA, with a fireside chat scheduled on Tuesday, August 13 at 10:30 a.m. ET. Additionally, Guardant Health will partake in a panel discussion on the Future of Cancer Screening at the UBS Genomic Medicine Summit in Dana Point, CA, on Wednesday, August 14 at 2:45 p.m. PT.
Live and archived webcasts of these sessions will be available on the “Investors” section of the Guardant Health website. Further details can be accessed at: www.guardanthealth.com.
Guardant Health (Nasdaq: GH) reported strong Q2 2024 financial results, with revenue increasing 29% to $177.2 million. The company raised its 2024 revenue guidance to $690-$700 million, representing 22-24% growth. Key highlights include:
1. Clinical testing volume up 14% and biopharma testing volume up 56% year-over-year
2. FDA approval of Shield as a first-line colorectal cancer screening option
3. Launch of upgraded Guardant360 on Smart Liquid Biopsy platform
4. Gross profit increased to $104.8 million, with a 59% gross margin
5. Net loss of $102.6 million, or $0.84 per share
The company's strong performance was driven by solid volume growth and improved reimbursement for Guardant360 tests.